Bioequivalence Between WE 941 OD and Brotizolam (Lendormin®) in Healthy Adult Males
Launched by BOEHRINGER INGELHEIM · Aug 15, 2014
Trial Information
Current as of May 09, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
MALE
Eligibility criteria
- Inclusion Criteria:
- • Age between 20 and 35 years
- • Weight between 50 and 80 kg
- • Obesity level within the range of +/- 20% of the standard weight according to the Body Mass Index (BMI) method
- • Judged as eligible as a study object following the screening test by the investigator
- • Volunteers to participate in the study, who are capable of giving written informed consent
- Exclusion Criteria:
- • Known hypersensitivity to drugs
- • History of drug or alcohol abuse
- • Received other investigational drug within 4 months of the trial drug administration
- • Had \> 400 mL of whole blood drawn within 3 months of the trial drug administration
- • Had \> 400 mL of blood components drawn within 1 month of the trial drug administration
- • Used any drug within 10 days of the trial drug administration
- • Engaged in strenuous exercise within 5 days of the trial drug administration
- • Consumed alcohol within 3 days of the trial drug administration
- • Judged as ineligible for the study participation by the investigator for a reason other than above
About Boehringer Ingelheim
Boehringer Ingelheim is a global, research-driven pharmaceutical company dedicated to improving health and quality of life through innovative therapies. Established in 1885 and headquartered in Ingelheim, Germany, the company focuses on the development of prescription medicines in key therapeutic areas, including respiratory diseases, cardiovascular health, oncology, and immunology. Boehringer Ingelheim is committed to advancing medical science through rigorous clinical trials and collaborative research, striving to bring novel treatments to patients while upholding the highest standards of safety and efficacy. With a strong emphasis on sustainability and corporate responsibility, the company aims to make a meaningful impact on global health challenges.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials